Lenvatinib, Tislelizumab Combined with Gemcitabine and Cisplatin (GPLET) in the Treatment of Advanced Cholangiocarcinoma

Last updated: February 5, 2025
Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University
Overall Status: Active - Recruiting

Phase

3

Condition

Digestive System Neoplasms

Abdominal Cancer

Liver Cancer

Treatment

Gemcitabine and cisplatin

Lenvatinib, tislelizumab, gemcitabine and cisplatin

Clinical Study ID

NCT05823311
2023-0175
  • Ages 18-75
  • All Genders

Study Summary

Cholangiocarcinoma (CCA) is a heterogeneous group of cancers arising from the epithelial cells of bile ducts. Because of highly aggressive malignancy, most of the patients are diagnosed at an advanced stage and lose the chance to undergo surgery.

As more effective and novel chemotherapy, targeted therapies, and immunotherapy become available, multiple treatments can be chosen for the patients with advanced CCA. Cytotoxic cell death during tumor chemotherapy triggers antigen release and induces strong anti-tumor effects of T cells. Tyrosine kinase inhibitors (TKI) can reduce the expression of PD-L1 and inhibit Treg cell infiltration, and together with immune checkpoint inhibitors, they can relieve tumor immunosuppressive microenvironment.

Therefore, the study aims to investigate the safety and efficacy of Lenvatinib, Tislelizumab combined with Gemcitabine plus Cisplatin (GPLET) in the treatment of advanced cholangiocarcinoma.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Histologically proven, unresectable advanced or metastatic cholangiocarcinomapatients.

  • Expected survival period > 12 weeks.

  • The World Health Organization (WHO) / ECOG physical status (PS) was 0 or 1.

  • There was at least one target lesion that matched the RECIST 1.1 criteria atbaseline.

  • Not previously received immunotherapy, including but not limited to CTLA 4, PD-L1or/and PD-1 inhibitors.

  • Adequate organ and bone marrow function, defined as follows: Hemoglobin (Hb)≥9.0g/dL; Neutrophils (ANC) ≥ 1.5* 10^9/L; Platelet (Pt) ≥ 50*10^9/L;ALT≤2.5×ULN（Normal upper limit); AST≤2.5×ULN.

  • Voluntary participation and signing of informed consent.

Exclusion

Exclusion Criteria:

  • Active or previously documented autoimmune disease or inflammatory disease.

  • Uncontrolled complications.

  • History of other primary malignancies.

  • Active infection.

  • Women who are pregnant or breastfeeding.

  • Patients with severe allergic history or specific constitution.

  • Researchers consider it inappropriate to participate in the test.

Study Design

Total Participants: 80
Treatment Group(s): 2
Primary Treatment: Gemcitabine and cisplatin
Phase: 3
Study Start date:
September 01, 2023
Estimated Completion Date:
December 31, 2027

Connect with a study center

  • The Second Affiliated Hospital, Zhejiang University School of Medicine

    Hangzhou, Zhejiang 310009
    China

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.